E Medical Tech M&A Analysis: Neuro, Orthopedic, Aesthetics And Specialty

A deal was announced June 7th, 2016, with Zimmer Biomet (ZBH) agreeing to acquire LDR Holdings (LDRH) for $1, a 65% premium, and paying 4.6X FY17 sales. LDRH specialized in spinal medical technologies and was the best in class name versus peers in terms of FY17 sales growth and gross margins. LDRH also had no long term debt and a healthy cash hoard with 5 years of consistent sales growth.

I expect many more deals in Med-Tech the rest of this year, though the pool of sub $2B market cap companies is relatively small.  I want to look across each industry within Med-Tech to find the best M&A candidate looking for growth and above industry-average margins as two keys for being an attractive target. 

In this next segment I am combining Neuro, Orthopedic, Aesthetics, and Specialty. In Neuro there is Penumbra (PEN) and Nevro (NVRO).  In Orthopedic there is CONMED (CNMD), Wright Medical (WMGI), and Integra (IART).  In Aesthetics Cynosure (CYNO) and Zeltiq (ZLTQ), and lastly in specialty there is Glaukos (GKOS), Intersect ENT (XENT), and Haemonetics (HAE).  The two names that immediately stand out with seeing unusual bullish options activity are Nevro (NVRO) and Wright Medical (WMGI).

The table below shows the comparison of key metrics.  Although CONMED (CNMD) and Haemonetics (HAE) are the clear value names at 1.5X and 1.6X FY17 Sales respectively, they also lag industry averages in sales growth as well as being margin laggards. CYNO and IART are both fairly attractive revenue and EPS growth names trading at 2.6X and 2.7X FY17 Sales respectively. NVRO and PEN are the clear sales growth leader plays, but also each are already priced at a major premium valuation. The specialty plays XENT and GKOS are both impressive sales growth names and have 80%+ margins leading in the peer group, trading 4X and 6X FY17 Sales respectively. That leaves WMGI which has above industry average gross margins above 70% and also seeing 12% forward sales growth, but is already trading more than 6X FY17 Sales.

1 2
View single page >> |

Not Investment Advice or Recommendation Any descriptions "to buy", "to sell", "long", "short" or any other trade related terminology should not be seen as a ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.